Bernstein Upgrades Amgen (AMGN) to Outperform
AMGN Hot Sheet
Rating Summary:6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Sanford C. Bernstein upgrades Amgen (Nasdaq: AMGN) from Market Perform to Outperform.
For more analyst ratings on AMGN click here.
Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
For more analyst ratings on AMGN click here.
Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
You May Also Be Interested In
- Analyst Sees Affymax's (AFFY) Omontys as Comparable to Amgen's (AMGN) Epogen; Raises AFFY Target to $21
- Roth Capital Upgrades Uroplasty (UPI) to Buy
- UPDATE: Regions (RF) Shares Jump as Rochdale's Bove Remains a Convicted Bull
Create E-mail Alert Related Categories
UpgradesRelated Entities
Sanford C. BernsteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
